secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcutis Biotherapeutics, Inc. (ARQT)
CIK:        0001787306
Form:       8-K
Filed at:   2022-05-05T23:59:59+00:00
Accession:  0001787306-22-000030
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcutis Q1 net loss $64.3M ($1.27/sh); cash $344.8M; roflumilast PDUFA July 29
------------------------------------------------------------------------------

- Net loss widened to $64.3M ($1.27 per share) from $36.0M ($0.76) in Q1 2021.
- Cash & securities $344.8M at Mar 31, down from $388.6M at Dec 31 2021; ATM added $14.5M.
- PDUFA action date July 29, 2022 for roflumilast cream in plaque psoriasis; commercial prep underway.
- Completed enrollment of pivotal Phase 3 trials for roflumilast foam in seborrheic dermatitis and scalp/body psoriasis.
- R&D spend $40.6M vs $21.6M; G&A $22.0M vs $14.5M, driven by clinical and launch preparations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787306/000178730622000030/0001787306-22-000030-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787306/000178730622000030/arqt-20220505.htm
  HTML page:      https://secwatch.observer/filing/0001787306-22-000030

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer